Cytokinetics, Incorporated (CYTK)
NEUTRALFundamental
32
Precio
$77.59
Capitalización Bursátil
$10.70B
Parte 1 · Cuánto vale la empresa
Resumen
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance y Liquidez
Ingresos
$68M
Últimos 12 meses (hasta 30/6/2026)
Beneficio Neto
$-894M
Últimos 12 meses (hasta 30/6/2026)
Flujo de Caja Libre
$-535M
Patrimonio Neto Total
$-660M
Pasivo Total
$2.08B
Ratio de Liquidez
6.66
Cobertura de Intereses
13.43
Deuda/EBITDA
-
Beneficio Por Acción
Ingresos y Beneficio Neto
Flujo de Caja Libre
Desglose de Ingresos
Estado histórico
Márgenes en el tiempo
La deuda en el tiempo
Cuánto pesa la deuda
Cuadro de crecimiento
Crecimiento — Ingresos
Estimación de Valor Justo
Valor Justo
$65.59
Precio Actual
$77.59
Margen de Seguridad
-18.3%
Rango de Valor Justo
$42.64 - $88.55
Métodos de Estimación
Métricas de Valoración
Ratio P/E
-
ROE
119.0%
Ratio P/B
-
P/FCF
-
Margen Bruto
-
ROIC
-32.1%
Radar de Rentabilidad
Value Creation (Economic Moat)
ROIC
-32.1%
WACC
8.0%
ROIC − WACC
-40.1 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Criterios de Análisis Fundamental
Superado (6)
- Price CAGR 20.26%
- Current Ratio
- Interest Coverage
- Low reliance on intangibles
- Revenue Growth 5Y 9.6%
- Analyst Consensus 89% Buy
Fallido (11)
- EPS shows upward trend
- ROIC -32.1%
- Operating Margin -1046.1%
- Positive Free Cash Flow
- Return on Tangible Assets
- DCF valuation (Overvalued)
- ROE -131.2%
- Earnings Surprise avg -12.0%
- Share Dilution 7.1%
- Net Margin Trend -1321.1% vs -707.2%
- Piotroski F-Score 2/9
No disponible (10)
- Gross Margin NaN%
- P/FCF NaN
- P/B Ratio NaN
- Dividend Payout NaN%
- Debt/Equity ratio
- CapEx intensity
- Debt/EBITDA
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-Score
Preocupaciones financieras graves
Calidad de los Beneficios
Baja calidad: investigue la contabilidad
Dilución de Acciones
Emitiendo nuevas acciones, diluyendo la participación
Gobernanza
Equipo Directivo
| Nombre | Cargo | Edad |
|---|---|---|
| Mr. Robert I. Blum | CEO, President & Director | 61 |
| Mr. Sung H. Lee | EVP & CFO | 55 |
| Mr. Jeffrey J. Hessekiel J.D. | Executive VP, Chief Legal & Administrative Officer | 56 |
| Dr. Fady Ibraham Malik FACC, M.D., Ph.D. | Executive Vice President of Research & Development | 61 |
| Mr. Andrew M. Callos | Executive VP & Chief Commercial Officer | 56 |
| Dr. James H. Sabry M.D., Ph.D. | Co-Founder & Chairman of Scientific Advisory Board | 67 |
| Dr. James A. Spudich Ph.D. | Co-Founder & Member of Scientific Advisory Board | 83 |
| Mr. Jeff Lotz | Vice President of Sales & Operations | - |
| Ms. Holly Laughlin | VP of Accounting & Corporate Controller | - |
| Mr. Steven M. Cook J.D. | Senior Vice President of Global Supply Chain Operations & Technical Operations | 66 |
Riesgo de Auditoría
5
Riesgo del Consejo
3
Riesgo de Compensación
8
Riesgo de Derechos del Accionista
7
Parte 2 · El precio y el momento de entrar
Esta parte no sirve para saber si la empresa vale: sirve para elegir cuándo comprarla, una vez que los fundamentales te han convencido. Dentro: análisis técnico, potencial, caídas históricas, exposición gamma.
Latest News
Recent headlines for CYTK, sourced from Markets Gazette.
- 3/9/2026POSITIVECytokinetics Insider Exercises Options Worth Over $920,000 as Heart Drug Hits the Market
A significant insider transaction at Cytokinetics Inc. has been reported, with an executive exercising stock options valued at over $920,000. This occurs as the company's cardiac drug candidate progresses towards market entry. The exercise of options by an insider often signals confidence in the company's future prospects and the value of its stock. Coupled with the impending market launch of a key therapeutic, this event suggests positive momentum for Cytokinetics, potentially attracting further investor interest and supporting share price appreciation.
- 2/24/2026NEUTRALCytokinetics (CYTK) Q4 2025 Earnings Transcript
The financial community is keenly awaiting the Q4 2025 earnings transcript from Cytokinetics (CYTK). While specific details are not yet available, the analysis of such documents is crucial for investors looking to assess the biopharmaceutical company's operational performance and future prospects. Transcripts offer direct insights into management discussions regarding financial results, drug pipeline advancements, and growth strategies. Analysts will closely monitor any indications concerning key drugs like omecamtiv mecarbil or aficamten, as well as projections for the current fiscal year. The current lack of specific data suggests a cautious approach, but the release is a standard event providing transparency and a basis for informed decisions.
via Markets Gazette